Univadis
  • Login
  • Sign up free
  • Reading list (0)
  • Favorites (0)
  • About You
  • Password
  • Email Subscriptions
  • Log Out
Back
  • Drug database by eMC
  • Suggested topics
  • COVID-19
  • Antibiotics
  • HIV
  • Vaccination
  • General Practice
    Specialties
    • All
    • Allergy
    • Anaesthetics
    • Cardiology
    • Dermatology
    • Elderly Medicine
    • Emergency Medicine
    • Endocrinology
    • Gastroenterology
    • General Medicine
    • General Practice
    • Gynaecology
    • Immunology
    • Infectious Diseases
    • Neurology
    • Nurses
    • Obstetrics
    • Oncology
    • Paediatrics
    • Pharmacists
    • Psychiatry
    • Radiology
    • Rheumatology
    • Surgery
    • Thoracic Medicine
    • Urology
  • News
  • Resources
  • Education
  • All
  • News
  • Resources
  • Education
          View more
          Suggested Keywords

          quiz

          • Question of the day
          • Previous questions
          • Leaderboard
          • Topic Challenge

          e-learning

          • Expert Presentations
          • Image Study
          • Patient Case
          Mobile
          • Discover the Univadis App

          Login

          Remember me
          Concise Daily Essentials,
          Curated for the Modern Clinician
          Register For Free
          On-going challenges
          All challenges
          • February 2021 Challenge Ends in 20h February 2021 Challenge
            20 questions available
          • All challenges

          Recommended for you

          • Recommended for you
          • Latest
          • Maintaining and optimising long term ARV therapy

            17mins - Expert presentations By Mike Youle

            Maintaining and optimising long term ARV therapy

            In this expert presentation, Professor Mike Youle, Royal Free Hospital, London discusses how antiretroviral therapy (ART) for people with HIV has changed over the years. He considers the issues that he takes into account to ensure the long term health of patients.

          • Epidemiology of multidrug resistant Gram-negative bacteria: Are we close to  the « post antibiotic era »?

            14mins - Expert presentations By Thierry Naas

            Epidemiology of multidrug resistant Gram-negative bacteria: Are we close to the « post antibiotic era »?

            Multidrug resistant bacteria are developing so fast that the burden of deaths due to these bacteria could be 10 million lives/year by 2050 - with an estimated cost of 1,000 trillion USD! In this short presentation, Dr. Naas highlights this crucial problem by explaining the mechanisms behind Gram-negative bacteria resistance as well as the epidemiology of extended spectrum ß-lactamase and carbapenem-resistance. He also presents possible solutions that can be used in this time-sensitive fight.

          Univadis

          Provided by Aptus Health, brings you unbiased, relevant medical news as well as helpful resources for your daily practice at no cost.

          • About us
          • Editorial Policy
          • Our editors

          Aptus Health does not endorse and is not responsible for the accuracy of the content, or for practices or standards of non-Aptus Health sources.

          • Terms of Use
          • Privacy Policy
          • Cookies

          Copyright © 2021 Aptus Health, Inc. All rights reserved.

          Univadis App
          Contact Us

          Our help center

          Email us

          We use cookies in order to provide you with a user-friendly and effective service as well as content adapted to your interests. We also use cookies to dynamically display Univadis ads and ads from our business partners on both Univadis and selected third party websites. By clicking or navigating the site, you agree to this use. Learn more - Manage preferences
          Univadis will update its Terms of Use and Privacy Policy on January 12, 2016. Please contact [email protected] if you have any questions about these changes. If you continue to use Univadis after January 12, 2016 the new Terms of Use and Privacy Policy will apply. By your continued use of Univadis, you accept and agree to these terms and policies.
          Univadis has updated its Terms of Use and Privacy Policy. Please contact [email protected] if you have any questions about these changes. By your continued use of Univadis, you accept and agree to these terms and policies.

          out of articles remaining this month Register for free Login

          out of articles remaining this month Login with Facebook Login with Facebook or login with your email

          You're leaving Univadis

          We want to make sure you would like leave Univadis and follow this external link: